Voss Capital’s Lantern Pharma LTRN Stock Holding History

Voss Capital’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$68.5K	–	65
2026 Q1	$68.5K	Hold	50,000	–	–	﹤0.01%	53
2025 Q4	$152K	Hold	50,000	–	–	0.01%	57
2025 Q3	$218K	Hold	50,000	–	–	0.01%	57
2025 Q2	$158K	Hold	50,000	–	–	0.01%	53
2025 Q1	$177K	Hold	50,000	–	–	0.01%	55
2024 Q4	$160K	Buy	+50,000	New	+$171K	0.01%	45
2021 Q1	–	Sell	-25,906	Closed	-$499K	–	50
2020 Q4	$499K	Sell	25,906 -9,161	-26%	-$158K	0.25%	40
2020 Q3	$661K	Buy	+35,067	New	+$508K	0.38%	42

Other funds holding LTRN

EAM

Empery Asset Management New York $86.5M AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Voss Capital's LTRN Position: Q2 2026 in Review

Voss Capital sold out of Lantern Pharma (LTRN) in Q2 2026, closing a stake of 50,000 shares — an estimated $68.5K sold.

Voss Capital first reported a position in LTRN in Q3 2020 and held it in 8 quarters. The position peaked at $661K in Q3 2020. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

Voss Capital reported no remaining Lantern Pharma position as of Q2 2026 after selling out during the quarter.
Voss Capital sold 50,000 Lantern Pharma shares in Q2 2026, an estimated $68.5K.
Voss Capital first reported a position in Lantern Pharma in Q3 2020 and held it in 8 quarters.
Voss Capital's Lantern Pharma position peaked at $661K in Q3 2020.
39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Voss Capital's 13F filing for Q2 2026, filed 14 Aug 2026.